Perspectives

Drug Pipeline Quarterly Update: March 2020

New drugs, new indications and news of note.

March 20, 2020

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

March 2020 Quarterly Traditional Pipeline Update
March 2020 Quarterly Specialty Pipeline Update

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit www.primetherapeutics.com and www.magellanrx.com, or follow us on Twitter at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

March 24, 2023

Look for Prime + Magellan Rx at AMCP 2023

Dr. Prerak Parikh (far left) and Dr. Sneha Sharma (far right) discuss trends…

Read More

Perspectives

March 23, 2023

Top female finance executive encourages DEI narrative

Over the past 30 years women’s careers in finance have seen significant progress,…

Read More

Perspectives

March 21, 2023

Top 10 acronyms in drug pipeline content, Part 2

News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…

Read More
View all news